BBLG

Bone Biologics
BBLG
Market cap $2.5M

1.19 USD

-0.10

7.75%

At close Nov 15, 4:00 PM EST

After hours

1.20

+0.01

0.84%

1 day

-7.75%

5 days

-11.19%

1 month

-19.59%

3 months

-19.05%

6 months

-47.58%

Year to date

-71.26%

1 year

-72.58%

5 years

-99.90%

10 years

-99.90%

About: Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Employees: 2

Healthcare Orthopedic, Prosthetic & Surgical Appliances & Supplies

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

163% more capital invested

Capital invested by funds: $69.7K [Q2] → $183K (+$114K) [Q3]

40% more funds holding

Funds holding: 5 [Q2] → 7 (+2) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.43% less ownership

Funds ownership: 5.22% [Q2] → 4.79% (-0.43%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BBLG.

See Analyst Rankings

Financial journalist opinion

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief ex.

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern tim.

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerc.

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot cli.

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Bone Biologics Announces Closing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in l.

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Announces Pricing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and acco.

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Reports Progress With NB1 Clinical Program

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical tr.

Bone Biologics Reports Progress With NB1 Clinical Program

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financ.

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all.

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Announces 1-for-8 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “.

Bone Biologics Announces 1-for-8 Reverse Stock Split

See News Rankings

Charts implemented using Lightweight Charts™